Results 191 to 200 of about 72,871 (224)

Lopinavir/ritonavir/ritonavir

Reactions Weekly, 2020
openaire   +1 more source

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

International Journal of Molecular Sciences, 2022
Nancy H C Loos, Jos H Beijnen, Alfred H Schinkel   +2 more
exaly  

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Clinical Microbiology and Infection, 2021
Nathan Peiffer-Smadja, Stéphane Jauréguiberry, André Cabie   +2 more
exaly  

Ritonavir

2022
openaire   +1 more source

Ritonavir

2010
Alison Duncan, Suzanne Crowe
openaire   +1 more source

Ritonavir

Reactions Weekly, 2017
  +4 more sources

Ritonavir

Reactions Weekly, 2002
openaire   +1 more source

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet, The, 2020
Peter Horby, Marion Mafham, Natalie Staplin   +2 more
exaly  

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Lancet, The, 2006
Joseph J Eron, Vicente Estrada, Benjamin Young   +2 more
exaly  

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
Jean-Michel Molina, Jaime Andrade-Villanueva   +1 more
exaly